全球陣發性睡眠性血尿症(PNH) 治療市場規模、佔有率、趨勢和成長分析報告（2026-2034 年）

預計陣發性睡眠性血尿症(PNH) 治療的市場規模將從 2025 年的 43.2 億美元成長到 2034 年的 88.4 億美元，2026 年至 2034 年的複合年成長率為 8.28%。

由於人們對罕見血液疾病的認知不斷提高以及診斷能力的進步，陣發性睡眠性血尿症(PNH) 治療的全球市場正穩步成長。篩檢的普及和流式細胞技術的進步使得早期檢測成為可能，促進了治療的廣泛應用。生物目標療法的日益普及顯著提高了患者的生存率和生活品質，鼓勵已開發市場和新興市場的醫療機構採用更先進的治療方案。

關鍵成長要素包括對補體抑制劑療法的大力研發投入以及新型單株抗體開發平臺的拓展。已開發國家對孤兒藥的監管支持和優惠的報銷政策進一步推動了市場擴張。此外，新興市場患者支援計畫的改善和醫療服務的可近性提高，也促進了診斷和治療率的提升，從而增強了整體市場需求。

展望未來，能夠延長給藥間隔並提高安全性的新一代療法有望惠及市場。正在進行的以口服和皮下製劑為重點的臨床試驗可望提升患者的用藥便利性和依從性。製藥公司與研究機構之間的策略合作可望加速創新，而亞太地區和拉丁美洲地區醫療基礎設施的擴建將在預測期內創造新的成長機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：陣發性睡眠性血尿症(PNH) 治療藥物的全球市場：依藥物類別分類

• 市場分析、洞察與預測
• 氨基喹啉
• 單株抗體
• 補體抑制劑
• 免疫系統調節劑
• 保護劑

第5章 全球陣發性睡眠性血尿症（PNH）治療藥物市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 靜脈注射
• 皮下注射
• 肌肉內部

第6章 全球陣發性睡眠性血尿症(PNH) 治療藥物市場：依患者族群分類

• 市場分析、洞察與預測
• 按年齡層
• 性別
• 地理分佈

第7章 陣發性睡眠性血尿症(PNH) 治療藥物的全球市場：按分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房
• 專科藥房

第8章 全球陣發性睡眠性血尿症(PNH) 治療藥物市場：依治療階段分類

• 市場分析、洞察與預測
• 一線治療
• 二線治療
• 支持性護理
• 移植後護理

第9章 全球陣發性睡眠性血尿症(PNH) 治療藥物市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Apellis Pharmaceuticals
  • Alexion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • CinnaGen Co
  • Ra Pharmaceuticals Inc
  • Amgen Inc
  • Achillion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Biocad

The Paroxysmal Nocturnal Hemoglobinuria Drug Market size is expected to reach USD 8.84 Billion in 2034 from USD 4.32 Billion (2025) growing at a CAGR of 8.28% during 2026-2034.

The global paroxysmal nocturnal hemoglobinuria (PNH) drug market is witnessing steady growth due to rising awareness of rare blood disorders and improved diagnostic capabilities. Increased screening and advancements in flow cytometry testing have enabled earlier detection, supporting treatment uptake. The growing availability of targeted biologic therapies has significantly improved patient survival rates and quality of life, encouraging healthcare providers to adopt advanced treatment options across developed and emerging markets.

Key growth drivers include strong research investments in complement inhibitor therapies and the expanding pipeline of novel monoclonal antibodies. Regulatory support for orphan drugs and favorable reimbursement policies in developed economies further stimulate market expansion. In addition, patient advocacy programs and improved healthcare access in emerging countries are contributing to increased diagnosis and treatment rates, strengthening overall market demand.

Looking ahead, the market is expected to benefit from next-generation therapies offering longer dosing intervals and improved safety profiles. Ongoing clinical trials focused on oral and subcutaneous formulations may enhance patient convenience and compliance. Strategic collaborations between pharmaceutical companies and research institutions are likely to accelerate innovation, while expanding healthcare infrastructure in Asia-Pacific and Latin America will create new growth opportunities over the forecast period.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Aminoquinolines
• Monoclonal Antibodies
• Complement Inhibitors
• Immune System Modulators
• Protective Agents

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

By Patient Demographics

• Age Group
• Gender
• Geographic Distribution

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

By Treatment Stage

• First-Line Therapy
• Second-Line Therapy
• Supportive Care
• Post-Transplant Care

COMPANIES PROFILED

• Apellis Pharmaceuticals, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc, CinnaGen Co, Ra Pharmaceuticals Inc, Amgen Inc, Achillion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, F HoffmannLa Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, Biocad
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Aminoquinolines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Complement Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immune System Modulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Protective Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY PATIENT DEMOGRAPHICS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Demographics
• 6.2. Age Group Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gender Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Geographic Distribution Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY TREATMENT STAGE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Treatment Stage
• 8.2. First-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Second-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Supportive Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Post-Transplant Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Route Of Administration
  • 9.2.3 By Patient Demographics
  • 9.2.4 By Distribution Channel
  • 9.2.5 By Treatment Stage
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Route Of Administration
  • 9.3.3 By Patient Demographics
  • 9.3.4 By Distribution Channel
  • 9.3.5 By Treatment Stage
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Route Of Administration
  • 9.4.3 By Patient Demographics
  • 9.4.4 By Distribution Channel
  • 9.4.5 By Treatment Stage
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Route Of Administration
  • 9.5.3 By Patient Demographics
  • 9.5.4 By Distribution Channel
  • 9.5.5 By Treatment Stage
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Route Of Administration
  • 9.6.3 By Patient Demographics
  • 9.6.4 By Distribution Channel
  • 9.6.5 By Treatment Stage
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Apellis Pharmaceuticals
  • 11.2.2 Alexion Pharmaceuticals Inc
  • 11.2.3 Akari Therapeutics Plc
  • 11.2.4 CinnaGen Co
  • 11.2.5 Ra Pharmaceuticals Inc
  • 11.2.6 Amgen Inc
  • 11.2.7 Achillion Pharmaceuticals Inc
  • 11.2.8 Alnylam Pharmaceuticals Inc
  • 11.2.9 F. Hoffmann-La Roche Ltd
  • 11.2.10 Novartis AG
  • 11.2.11 Regeneron Pharmaceuticals Inc
  • 11.2.12 Biocad